Related Experiment Video
Updated: May 11, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.3K
Primary Tauopathy With Logopenic/Semantic Mixed Progressive Aphasia and Frontotemporal Dementia-like Behavior
Akihiro Takasaki1, Yoshiyuki Nishio2, Yuto Satake1
1Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan.
Summary
This study details two cases presenting early symptoms of Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD). Findings suggest a novel tauopathy syndrome distinct from typical AD.
Area of Science:
- Neuroscience
- Neuropathology
- Clinical Neurology
Background:
- Alzheimer disease (AD) and frontotemporal lobar degeneration (FTLD) are distinct neurodegenerative disorders.
- Early clinical overlap between AD and FTLD can complicate diagnosis.
- Tau pathology is implicated in both AD and FTLD, but with different characteristics.
Purpose of the Study:
- To describe two cases with overlapping early clinical symptoms of AD and FTLD.
- To investigate the underlying neuropathology in these cases.
- To propose a potential new syndrome associated with non-Alzheimer tauopathy.
Main Methods:
- Case study of two individuals with complex neurological symptoms.
- Clinical assessment focusing on language and behavioral changes.
- Multimodal neuroimaging (MRI, PET) to evaluate brain structure and function.
- Pathological examination to determine underlying neuropathology.
Main Results:
- Patients exhibited phonological deficits (suggestive of AD) and semantic impairment with behavioral changes (suggestive of FTLD).
- Neuroimaging revealed primary tauopathy with 3/4-repeat tau isoforms.
- Amyloid deposition, characteristic of AD, was notably absent.
Conclusions:
- The findings suggest a previously unrecognized clinical syndrome.
- This syndrome appears associated with non-Alzheimer primary tauopathy.
- Distinguishing between AD and FTLD early on is crucial for accurate diagnosis and management.
Related Concept Videos
Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
Dementia
65
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
65
Parkinson's Disease: Overview
310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Amyloid Fibrils
9.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.0K

